無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の子宮頸がん診断市場の予測

Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022

発行 Azoth Analytics 商品コード 601317
出版日 ページ情報 英文 192 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.41円で換算しております。
Back to Top
世界の子宮頸がん診断市場の予測 Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022
出版日: 2018年01月26日 ページ情報: 英文 192 Pages
概要

当レポートでは、世界の子宮頸がん診断市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題、機会、主要企業などについて、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 子宮頸がんの見通し

第5章 世界の子宮頸がん診断市場:成長率と予測

  • 金額別

第6章 世界の子宮頸がん診断市場:分析

  • タイプ別
  • 年齢層別

第7章 世界の子宮頸がん診断市場:地域別分析

  • 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 市場力学

  • 市場促進要因
  • 市場抑制要因

第9章 市場動向

第10章 ファイブフォース分析

第11章 SWOT分析

第12章 サプライチェーン分析

第13章 価格分析

第14章 競合情勢

  • 企業シェア分析
  • 製品ベンチマーキング
  • 最近の製品承認

第15章 政策・規制情勢

第16章 企業プロファイル

  • Hologic
  • Abott Laboratories
  • Roche
  • Guided Therapeutics
  • Becton, Dickinson and Company
  • Qiagen
  • Quest Diagnostics
  • Arbor Vita Corporation
図表

List of Figures

  • Figure 1: Global Cervical Cancer Diagnostics Market Size, By Value, 2012-2016 (USD Million)
  • Figure 2: Global Cervical Cancer Diagnostics Market Size, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 3: Healthcare Costs Per Capita, By Select Countries, 2015 (USD)
  • Figure 4: World Female Population Estimates, 2017 (In Millions)
  • Figure 5: Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region
  • Figure 6: Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000 women)
  • Figure 7: Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)
  • Figure 8: Global Cervical Cancer Diagnostics Market Size, By Type, 2016 (%)
  • Figure 9: Global Cervical Cancer Diagnostics Market Size, By Type, 2022 (%)
  • Figure 10: Global PAP Test Market, By Value, 2012-2016 (USD Million)
  • Figure 11: Global PAP Test Market, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 12: Global HPV Test Market, By Value, 2012-2016 (USD Million)
  • Figure 13: Global HPV Test Market, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 14: Global Colposcopy Test Market, By Value, 2012-2016 (USD Million)
  • Figure 15: Global Colposcopy Test Market, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 16: Global Cervical Biopsies Market, By Value, 2012-2016 (USD Million)
  • Figure 17: Global Cervical Biopsies Market, By Value, Forecast, 2017-2022, (USD Million)
  • Figure 18: Global Cervical Cancer Diagnostics Market Size, By Age Group, 2016 (%)
  • Figure 19: Global Cervical Cancer Diagnostics Market Size, By Age Group, 2022 (%)
  • Figure 20: Global Cervical Cancer Diagnostics Market, By Age Group (Below 35 years), By Value, 2012-2016 (USD Million)
  • Figure 21: Global Cervical Cancer Diagnostics Market, By Age Group (Below 35 years), By Value, Forecast, 2017-2022 (USD Million)
  • Figure 22: Global Cervical Cancer Diagnostics Market, By Age Group (35 years and above), By Value, 2012-2016 (USD Million)
  • Figure 23: Global Cervical Cancer Diagnostics Market, By Age Group (35 years and above), By Value, Forecast, 2017-2022 (USD Million)
  • Figure 24: Global Cervical Cancer Diagnostics Market Size, By Region, 2016 (%)
  • Figure 25: Global Cervical Cancer Diagnostics Market Size, By Region, 2022 (%)
  • Figure 26: North America Cervical Cancer Diagnostics Market Size, By Value, 2012-2016 (USD Million)
  • Figure 27: North America Cervical Cancer Diagnostics Market Size, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 28: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
  • Figure 29: North America GDP, 2012-2015 (USD Trillion)
  • Figure 30: North America GDP, By Select Country, 2016 (USD Trillion)
  • Figure 31: United States of America, Per Capita Expenditure on Healthcare, 2012-2016 (USD)
  • Figure 32: Canada, Per Capita Expenditure on Healthcare, 2012-2016 (USD)
  • Figure 33: United States of America, Female Population in the age group 15-64, 2012-2016
  • Figure 34: Canada, Female Population in the age group 15-64, 2012-2016
  • Figure 35: North America Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 36: North America Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 37: U.S. Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 38: U.S Health Spending, By Service or Product, 2016 (%)
  • Figure 39: U.S Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 40: U.S Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 41: Canada Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 42: Canada Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 43: Canada Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 44: North America Cervical Cancer Diagnostics Market, Country Share, 2012-2016 (% of Total)
  • Figure 45: North America Cervical Cancer Diagnostics Market, Country Share, Forecast, 2017-2022 (% of Total)
  • Figure 46: Europe Cervical Cancer Diagnostics Market Size, By Value, 2012-2016 (USD Million)
  • Figure 47: Europe Cervical Cancer Diagnostics Market Size, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 48: Europe, GDP, By Select Country, 2016, (USD Billion)
  • Figure 49: Europe Health Spending Per Capita, By Select Country, 2016 (USD)
  • Figure 50: United Kingdom, Per Capita Expenditure on Healthcare, 2012-2016 (USD)
  • Figure 51: Germany, Per Capita Expenditure on Healthcare, 2012-2016 (USD)
  • Figure 52: United Kingdom, Female Population in the age group 15-64, 2012-2016
  • Figure 53: Germany, Female Population in the age group 15-64, 2012-2016
  • Figure 54: Europe Medical Technology Market Based on Manufacturer Prices, By Country, 2016 (%)
  • Figure 55: Europe Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 56: Europe Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 57: Germany Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 58: Germany Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 59: Germany Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 60: U.K Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 61: U.K Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 62: U.K Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 63: Europe Cervical Cancer Diagnostics Market, Country Share, 2012-2016 (% of Total)
  • Figure 64: Europe Cervical Cancer Diagnostics Market, Country Share, Forecast, 2017-2022 (% of Total)
  • Figure 65: APAC Cervical Cancer Diagnostics Market Size, By Value, 2012-2016 (USD Million)
  • Figure 66: APAC Cervical Cancer Diagnostics Market Size, By Value, Forecast, 2017-2022 (USD Million)
  • Figure 67: APAC, GDP, By Select Country, 2016, (USD Billion)
  • Figure 68: APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD)
  • Figure 69: China, Female Population in the age group 15-64, 2012-2016
  • Figure 70: India, Female Population in the age group 15-64, 2012-2016
  • Figure 71: India, Degree of Urbanization, 2012-2016 (in %)
  • Figure 72: China, Degree of Urbanization, 2012-2016, (in %)
  • Figure 73: APAC Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 74: APAC Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 75: China Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 76: China Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 77: China Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 78: India Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 79: India Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 80: India Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 81: APAC Cervical Cancer Diagnostics Market, Country Share, 2012-2016 (% of Total)
  • Figure 82: APAC Cervical Cancer Diagnostics Market, Country Share, Forecast, 2017-2022 (% of Total)
  • Figure 83: ROW Cervical Cancer Diagnostics Market Size, By Value, 2012-2016 (USD Million)
  • Figure 84: ROW Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 85: ROW Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 86: Brazil Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 87: Brazil, Female Population in the age group 15-64, 2012-2016
  • Figure 88: Brazil, Degree of Urbanization, 2012-2016 (in %)
  • Figure 89: Brazil Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 90: Brazil Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 91: Mexico Cervical Cancer Diagnostics Market Size, By Value, 2012-2022 (USD Million)
  • Figure 92: Mexico, Female Population in the age group 15-64, 2012-2016
  • Figure 93: Mexico, Degree of Urbanization, 2012-2016 (in %)
  • Figure 94: Mexico Cervical Cancer Diagnostics Market: By Type, By Value, 2012-2022 (USD Million)
  • Figure 95: Mexico Cervical Cancer Diagnostics Market: By Age Group, By Value, 2012-2022 (USD Million)
  • Figure 96: ROW Cervical Cancer Diagnostics Market, Country Share, 2012-2016 (% of Total)
  • Figure 97: ROW Cervical Cancer Diagnostics Market, Country Share, Forecast, 2017-2022 (% of Total)
  • Figure 98: Global Cervical Cancer Diagnostics Market, By Company Share, 2016 (%)
  • Figure 99: Hologic, Revenue, 2013-2017 (USD Billion)
  • Figure 100: Hologic, Revenue, By Geography, 2017 (%)
  • Figure 101: Hologic, Revenue, By Segment, 2017 (%)
  • Figure 102: Abbott Laboratories, Revenue, 2012-2016 (USD Million)
  • Figure 103: Abobott Laboratories, Revenue, By Segment, 2016 (%)
  • Figure 104: Abbott, Revenue, By Geography, 2016 (%)
  • Figure 105: Roche, Revenue, 2012-2016 (USD Million)
  • Figure 106: Roche, Revenue, By Segment, 2016 (%)
  • Figure 107: Roche, Revenue, By Segment, 2016 (%)
  • Figure 108: Guided Therapeutics, Sales, 2012-2016 (USD thousands)
  • Figure 109: BD, Revenue, 2012-2016 (USD Million)
  • Figure 110: BD, Revenue, By geography, 2017 (%)
  • Figure 111: BD, Revenue, By Segment, 2017 (%)
  • Figure 112: Qiagen, Revenue, 2012-2016 (USD Millions)
  • Figure 113: Qiagen, Revenue, By geography, 2016 (%)
  • Figure 114: Qiagen, Revenue, By Product Categories, 2016 (%)
  • Figure 115: Quest Diagnostics, Revenue, 2012-2016 (USD Millions)
  • Figure 116: Qiagen, Revenue, By Business Segments, 2016

List of Tables

  • Table A: List of Abbreviations
  • Table B: Cervical Cancer Flowchart
  • Table C: Cervical Cancer Screening Recommendations
  • Table D: Cervical Cancer Diagnostics Segmentation Flowchart
  • Table E: Medical Tourism Market Drivers
  • Table F: Medical Tourism Index, By Region and Top Destinations
  • Table G: Recent Company Acquisitions in Cervical Cancer Diagnostics Market
  • Table H: HPV-Associated and HPV-Attributable Cancer Statistics, U.S, 2015
  • Table I: Major Players in cervical cancer diagnostics market in North America
  • Table J: Europe, Female Population aged 15+, By Region, 2017, (In Millions)
  • Table K: Major Players in cervical cancer diagnostics market in Europe
  • Table L: Pricing Analysis of PAP TEST
  • Table M: Pricing Analysis of HPV TEST
  • Table N: Pricing Analysis of Colposcopy Test
  • Table O: Pricing Analysis of Cervical Biopsy
  • Table P: Roche, Growth Strategy
  • Table Q: Product Benchmarking of Key Industry Players, By Type
  • Table R: Product Benchmarking of Key Industry Players, By Type
  • Table S: Recent Product Approvals of Key Industry Players in Cervical Cancer Diagnostics Market
目次

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global cervical cancer diagnostics market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (Below 35 years and 35 years & above), By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (U.S, Canada, Germany, U.K, China, India, Mexico and Brazil).

According to Azoth Analytics research report, "Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022", global market is projected to display a modest growth represented by a CAGR of 5.69% during 2017 - 2022, chiefly driven by growing healthcare awareness and increasing expenditure in healthcare sector.

On account of growing urbanization, there has been rising awareness regarding the benefits of periodic screening for cervical cancer. Additionally, growing female population in concurrence with medical infrastructural developments in emerging economies has been instrumental in boosting the demand for cervical cancer diagnostics. Amongst the type of cervical cancer diagnostic tests, cytology based screening solutions such as Pap and HPV, held the majority market share of more than 50%, by value, in the year 2016. Moreover, HPV tests are gaining market share on account of advantageous characteristics such as reliable and accurate result, reasonable cost, longer time gap between tests, and so on. Among the regions, North America and Europe together represents the largest regional market for global cervical cancer diagnostics market, chiefly driven by high per capita expenditure on healthcare, as well as availability of advanced medical infrastructure.

The report titled, "Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022", has covered and analysed the potential of cervical cancer diagnostics market across the globe and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global cervical cancer diagnostics market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

  • Global Cervical Cancer Diagnostics Market, By Value
  • Global Cervical Cancer Diagnostics Market, By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Value
  • Global Cervical Cancer Diagnostics Market, By Age Group (Below 35 years and 35 years and above), By Value

Regional Markets - North America, Europe, Asia Pacific and Rest of the World (Actual Period: 2012-2016, Forecast Period: 2017-2022)

  • Cervical Cancer Diagnostics Market, By Value
  • Cervical Cancer Diagnostics Market, By Type, By Value
  • Cervical Cancer Diagnostics Market, By Age Group, By Value

Country Analysis - U.S, Canada, U.K, Germany, China, India, Brazil and Mexico (Actual Period: 2012-2016, Forecast Period: 2017-2022)

  • Cervical Cancer Diagnostics Market, By Value
  • Cervical Cancer Diagnostics Market, By Type, By Value
  • Cervical Cancer Diagnostics Market, By Age Group, By Value

Other Report Highlights

  • Market Dynamics - Trends, Drivers, Restraints
  • Porter Five Force Analysis
  • SWOT Analysis
  • Supply Chain Analysis
  • Pricing Analysis
  • Product Benchmarking of Key Industry Players
  • Recent Product Approvals of Key Industry Players
  • Policy and Regulation
  • Company Analysis - Hologic, Roche, Abott Laboratories, Guided Therapeutics, Becton, Dickinson and Company, Qiagen, Quest Diagnostics, Arbor Vita Corporation.
  • Company Share Analysis

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Cervical Cancer Outlook

5. Global Cervical Cancer Diagnostics Market: Growth and Forecast

  • 5.1. By Value (2012-2016)
  • 5.2. By Value (2012-2016)

6. Global Cervical Cancer Diagnostics Market: An Analysis

  • 6.1. Global Cervical Cancer Diagnostics Market Size, By Type
    • 6.1.1. Global Cervical Cancer Diagnostics Market Size, By Type, 2016 (%)
    • 6.1.2. Global Cervical Cancer Diagnostics Market Size, By Type, 2022 (%)
    • 6.1.3. Global Pap Test Market, By Value (2012-2022)
    • 6.1.4. Global HPV Test Market, By Value (2012-2022)
    • 6.1.5. Global Colposcopy Market, By Value (2012-2022)
    • 6.1.6. Global Cervical Biopsies Market, By Value (2012-2022)
  • 6.2. Global Cervical Cancer Diagnostics Market Size, By Age Group
    • 6.2.1. Global Cervical Cancer Diagnostics Market Size, By Age Group, 2016 (%)
    • 6.2.2. Global Cervical Cancer Diagnostics Market Size, By Age Group, 2022 (%)
    • 6.2.3. Global Cervical Cancer Diagnostics Market, By Age Group (Below 35 years), By Value (2012-2022)
    • 6.2.4. Global Cervical Cancer Diagnostics Market, By Age Group (35 years and above),
    • 6.2.5. By Value (2012-2022)

7. Global Cervical Cancer Diagnostics Market: Regional Analysis

  • 7.1. Global Cervical Cancer Diagnostics Market Size, By Region: Breakdown (%)
    • 7.1.1. Global Cervical Cancer Diagnostics Market Size, By Region, 2016 (%)
    • 7.1.2. Global Cervical Cancer Diagnostics Market Size, By Region, 2022 (%)
  • 7.2. North America Cervical Cancer Diagnostics Market: An Analysis
    • 7.2.1. By Value (2012-2016)
    • 7.2.2. By Value (2017-2022)
    • 7.2.3. By Type, By Value (2012-2022)
    • 7.2.4. By Age Group, By Value (2012-2022)
  • 7.3. North America Cervical Cancer Diagnostics Market: Country Analysis (U.S and Canada)
    • 7.3.1. U.S Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.3.2. U.S Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.3.3. U.S Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
    • 7.3.4. Canada Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.3.5. Canada Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.3.6. Canada Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
  • 7.4. Europe Cervical Cancer Diagnostics Market: An Analysis
    • 7.4.1. By Value (2012-2016)
    • 7.4.2. By Value (2017-2022)
    • 7.4.3. By Type, By Value (2012-2022)
    • 7.4.4. By Age Group, By Value (2012-2022)
  • 7.5. Europe Cervical Cancer Diagnostics Market: Country Analysis (Germany and U.K)
    • 7.5.1. Germany Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.5.2. Germany Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.5.3. Germany Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
    • 7.5.4. U.K Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.5.5. U.K Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.5.6. U.K Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
  • 7.6. APAC Cervical Cancer Diagnostics Market: An Analysis
    • 7.6.1. By Value (2012-2016)
    • 7.6.2. By Value (2017-2022)
    • 7.6.3. By Type, By Value (2012-2022)
    • 7.6.4. By Age Group, By Value (2012-2022)
  • 7.7. APAC Cervical Cancer Diagnostics Market: Country Analysis (China and India)
    • 7.7.1. China Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.7.2. China Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.7.3. China Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
    • 7.7.4. India Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.7.5. India Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.7.6. India Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
  • 7.8. ROW Cervical Cancer Diagnostics Market: An Analysis
    • 7.8.1. By Value (2012-2016)
    • 7.8.2. By Value (2017-2022)
    • 7.8.3. By Type, By Value (2012-2022)
    • 7.8.4. By Age Group, By Value (2012-2022)
  • 7.9. ROW Cervical Cancer Diagnostics Market: Country Analysis (Brazil and Mexico)
    • 7.9.1. Brazil Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.9.2. Brazil Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.9.3. Brazil Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)
    • 7.9.4. Mexico Cervical Cancer Diagnostics Market, By Value (2012-2022)
    • 7.9.5. Mexico Cervical Cancer Diagnostics Market, By Type, By Value (2012-2022)
    • 7.9.6. Mexico Cervical Cancer Diagnostics Market, By Age Group, By Value (2012-2022)

8. Global Cervical Cancer Diagnostics Market Dynamics

  • 8.1. Global Cervical Cancer Diagnostics Market Drivers
  • 8.2. Global Cervical Cancer Diagnostics Market Restraints

9. Global Cervical Cancer Diagnostics Market Trends

10. Porter Five Force Analysis

11. SWOT Analysis

12. Supply Chain Analysis

13. Pricing Analysis

14. Competitive Landscape

  • 14.1. Company Share Analysis of Key Industry Players
  • 14.2. Product Benchmarking of Key Industry Players
  • 14.3. Recent Product Approvals of Key Industry Players

15. Policy and Regulatory Landscape

16. Company Profiles

  • 16.1. Hologic
  • 16.2. Abott Laboratories
  • 16.3. Roche
  • 16.4. Guided Therapeutics
  • 16.5. Becton, Dickinson and Company
  • 16.6. Qiagen
  • 16.7. Quest Diagnostics
  • 16.8. Arbor Vita Corporation
Back to Top